Home/Filings/4/0000950170-25-013878
4//SEC Filing

DENYES NANCY 4

Accession 0000950170-25-013878

CIK 0001339970other

Filed

Feb 3, 7:00 PM ET

Accepted

Feb 4, 6:11 PM ET

Size

8.9 KB

Accession

0000950170-25-013878

Insider Transaction Report

Form 4
Period: 2025-02-03
DENYES NANCY
General Counsel
Transactions
  • Exercise/Conversion

    Common Stock

    2025-02-03+2,68727,454 total
  • Exercise/Conversion

    Restricted Stock Unit

    2025-02-032,6872,687 total
    Common Stock (2,687 underlying)
  • Sale

    Common Stock

    2025-02-04$3.78/sh899$3,39826,555 total
Footnotes (5)
  • [F1]Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
  • [F2]Restricted stock units convert into common stock on a one-for-one basis.
  • [F3]Includes 2,500 shares acquired on November 15, 2024 under the Company's 2015 Employee Purchase Plan.
  • [F4]Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.
  • [F5]The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.

Documents

1 file

Issuer

aTYR PHARMA INC

CIK 0001339970

Entity typeother

Related Parties

1
  • filerCIK 0001640869

Filing Metadata

Form type
4
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 6:11 PM ET
Size
8.9 KB